RECA-1 Inhibitors
RECA-1 inhibitors, as discussed here, refer to a group of chemicals that can either directly or indirectly influence the activities of the RecA protein or its analogous functions. RecA is fundamentally involved in DNA repair and homologous recombination. These chemicals, therefore, target the DNA processes or structures to which RecA is inherently linked.
Many of the inhibitors listed, such as Mitomycin C, function by introducing alterations to the DNA structure, which can saturate or interfere with the repair capabilities of RecA. Others, like Ciprofloxacin and Norfloxacin, engage with enzymes like DNA gyrase, thereby indirectly modulating the accessibility or availability of DNA substrates that RecA usually acts upon. Intercalating agents like Daunorubicin and Doxorubicin insert themselves between the DNA bases, leading to disruptions in the DNA processes and structures that RecA is crucially a part of. A separate set, including 5-fluorouracil and Hydroxyurea, hinder DNA synthesis or introduce anomalies, in turn influencing the roles of RecA in the overall DNA maintenance landscape. Collectively, while these chemicals don't directly inhibit RecA, their overarching effects on DNA processes ensure a modulation of RecA's functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
A PARP inhibitor that prevents DNA repair in cancer cells by blocking the PARP enzyme, leading to increased DNA damage and cell death. Its action indirectly affects homologous recombination repair mechanisms, potentially inhibiting RECA-1-like functions. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
Another PARP inhibitor, rucaparib, enhances DNA damage in cancer cells by inhibiting PARP, a key enzyme in the DNA repair process. This inhibition can indirectly suppress pathways involving RECA-1-like protein activities in DNA repair. | ||||||
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
Targets PARP enzymes, disrupting DNA repair pathways and indirectly inhibiting processes that may involve RECA-1 analogs. Its mechanism suggests a potential reduction in the efficiency of homologous recombination. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $182.00 $275.00 $726.00 | 3 | |
A PARP inhibitor used to induce synthetic lethality in tumor cells deficient in BRCA1/2. By blocking PARP, it indirectly impacts pathways that could involve RECA-1-like proteins, suppressing their roles in DNA repair. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Inhibits DNA topoisomerase I, preventing DNA relegation and leading to DNA damage accumulation. This mechanism indirectly influences pathways where RECA-1 analogs might play a role, particularly in DNA repair processes. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Targets DNA topoisomerase II, causing DNA strand breaks and affecting cell cycle progression. Its action could indirectly inhibit DNA repair mechanisms, including those potentially involving RECA-1-like proteins. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Acts as an alkylating agent, cross-linking DNA strands and inhibiting DNA synthesis and repair. This could indirectly affect RECA-1-like functions by impeding the homologous recombination repair pathway. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Forms DNA adducts, leading to DNA damage and apoptosis. Its effect on DNA repair pathways could indirectly inhibit functions of proteins similar to RECA-1, involved in homologous recombination. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
Inhibits the ATR kinase, a key player in the DNA damage response, potentially affecting the efficiency of DNA repair processes including those involving RECA-1-like proteins. | ||||||
Ceralasertib | 1352226-88-0 | sc-507439 | 10 mg | $573.00 | ||
An ATR inhibitor that compromises DNA damage response and repair, potentially impacting the function of RECA-1 analogs in the homologous recombination pathway. | ||||||